Excelsior Medical Co., Ltd. (4104.TW)
TWD 84.9
(6.26%)
TWD 84.9
(6.26%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 7.16 Billion TWD | 15.87% |
| 2022 | 6.18 Billion TWD | 15.41% |
| 2021 | 5.35 Billion TWD | 21.12% |
| 2020 | 4.42 Billion TWD | -13.8% |
| 2019 | 5.13 Billion TWD | -8.96% |
| 2018 | 5.63 Billion TWD | -18.6% |
| 2017 | 6.92 Billion TWD | -18.68% |
| 2016 | 8.51 Billion TWD | 14.53% |
| 2015 | 7.43 Billion TWD | 5.81% |
| 2014 | 7.02 Billion TWD | 4.75% |
| 2013 | 6.7 Billion TWD | 1.6% |
| 2012 | 6.6 Billion TWD | 4.25% |
| 2011 | 6.33 Billion TWD | 12.86% |
| 2010 | 5.61 Billion TWD | 25.19% |
| 2009 | 4.48 Billion TWD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 7.94 Billion TWD | 10.81% |
| 2024 Q2 | 6.84 Billion TWD | -13.81% |
| 2023 Q4 | 7.16 Billion TWD | 6.32% |
| 2023 FY | 7.16 Billion TWD | 15.87% |
| 2023 Q1 | 6.71 Billion TWD | 8.65% |
| 2023 Q2 | 6.48 Billion TWD | -3.56% |
| 2023 Q3 | 6.74 Billion TWD | 4.02% |
| 2022 Q4 | 6.18 Billion TWD | 2.42% |
| 2022 FY | 6.18 Billion TWD | 15.41% |
| 2022 Q2 | 6.19 Billion TWD | 5.15% |
| 2022 Q1 | 5.89 Billion TWD | 10.02% |
| 2022 Q3 | 6.03 Billion TWD | -2.59% |
| 2021 FY | 5.35 Billion TWD | 21.12% |
| 2021 Q3 | 5.04 Billion TWD | -4.49% |
| 2021 Q4 | 5.35 Billion TWD | 6.32% |
| 2021 Q1 | 5.16 Billion TWD | 16.61% |
| 2021 Q2 | 5.27 Billion TWD | 2.29% |
| 2020 Q3 | 4.31 Billion TWD | -5.13% |
| 2020 Q4 | 4.42 Billion TWD | 2.57% |
| 2020 FY | 4.42 Billion TWD | -13.8% |
| 2020 Q2 | 4.54 Billion TWD | -22.0% |
| 2020 Q1 | 5.83 Billion TWD | 13.58% |
| 2019 Q3 | 5.42 Billion TWD | -14.17% |
| 2019 Q2 | 6.31 Billion TWD | 7.06% |
| 2019 Q1 | 5.89 Billion TWD | 4.61% |
| 2019 Q4 | 5.13 Billion TWD | -5.3% |
| 2019 FY | 5.13 Billion TWD | -8.96% |
| 2018 Q2 | 6.61 Billion TWD | 1.51% |
| 2018 Q4 | 5.63 Billion TWD | -0.19% |
| 2018 FY | 5.63 Billion TWD | -18.6% |
| 2018 Q1 | 6.51 Billion TWD | -5.92% |
| 2018 Q3 | 5.64 Billion TWD | -14.59% |
| 2017 Q3 | 6.71 Billion TWD | -9.13% |
| 2017 FY | 6.92 Billion TWD | -18.68% |
| 2017 Q4 | 6.92 Billion TWD | 3.17% |
| 2017 Q2 | 7.38 Billion TWD | 4.52% |
| 2017 Q1 | 7.06 Billion TWD | -17.0% |
| 2016 Q2 | 8.2 Billion TWD | 4.7% |
| 2016 Q1 | 7.83 Billion TWD | 5.38% |
| 2016 FY | 8.51 Billion TWD | 14.53% |
| 2016 Q4 | 8.51 Billion TWD | 5.92% |
| 2016 Q3 | 8.04 Billion TWD | -2.0% |
| 2015 FY | 7.43 Billion TWD | 5.81% |
| 2015 Q1 | 6.66 Billion TWD | -5.15% |
| 2015 Q4 | 7.43 Billion TWD | 1.54% |
| 2015 Q2 | 7.74 Billion TWD | 16.18% |
| 2015 Q3 | 7.32 Billion TWD | -5.44% |
| 2014 FY | 7.02 Billion TWD | 4.75% |
| 2014 Q2 | 6.94 Billion TWD | 6.02% |
| 2014 Q3 | 6.16 Billion TWD | -11.13% |
| 2014 Q4 | 7.02 Billion TWD | 13.96% |
| 2014 Q1 | 6.54 Billion TWD | -2.44% |
| 2013 Q3 | 7.07 Billion TWD | -3.73% |
| 2013 Q4 | 6.7 Billion TWD | -5.23% |
| 2013 FY | 6.7 Billion TWD | 1.6% |
| 2013 Q2 | 7.35 Billion TWD | 7.34% |
| 2013 Q1 | 6.85 Billion TWD | 3.74% |
| 2012 Q1 | 6.65 Billion TWD | 5.05% |
| 2012 FY | 6.6 Billion TWD | 4.25% |
| 2012 Q4 | 6.6 Billion TWD | -3.83% |
| 2012 Q3 | 6.86 Billion TWD | 0.15% |
| 2012 Q2 | 6.85 Billion TWD | 3.03% |
| 2011 Q3 | 8.02 Billion TWD | 15.86% |
| 2011 Q1 | 6.21 Billion TWD | 10.7% |
| 2011 Q2 | 6.93 Billion TWD | 11.54% |
| 2011 Q4 | 6.33 Billion TWD | -21.1% |
| 2011 FY | 6.33 Billion TWD | 12.86% |
| 2010 Q4 | 5.61 Billion TWD | 0.0% |
| 2010 FY | 5.61 Billion TWD | 25.19% |
| 2009 FY | 4.48 Billion TWD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Apex Medical Corp. | 883.97 Million TWD | -710.766% |
| OK Biotech Co., Ltd. | 672.26 Million TWD | -966.094% |
| Applied BioCode Corporation | 332.21 Million TWD | -2057.315% |